Recursion Pharmaceuticals uses high-dimensional data and modern approaches to generate predictive results for drug discovery and development. The company has strengthened its tech stack through ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...
Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...
Recursion expects to share Phase II data for REC-994 in the first half of 2025, through a publication, webinar, or presentation at a medical conference. By the end of this year, Recursion plans to ...
At a job interview on Friday, I had to write code, and one of the things that came up when we were talking about implementation of a concept was recursion. The director of the group said to me "Don't ...
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
PHILADELPHIA - Recursion (NASDAQ: RXRX), a clinical stage TechBio company with a market capitalization of $2.27 billion, has entered into a licensing agreement with HealthVerity to utilize its ...
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback